



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم

جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of
15-25- c and relative humidity 20-40%



شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم

بعض الوثائق الأصلية تالفة

بالرسالة صفحات لم ترد بالاصل

Design, Synthesis & Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine Derivatives as Tyrosine Kinase Inhibitors

A thesis presented by

Ahmad Samir Ibrahim El-Khouly

B.Sc. Pharm. Sci.

Faculty of pharmacy, Zagazig University

2002

Submitted for the partial fulfillment for

The Degree of Master of Pharmaceutical Sciences

(Pharmaceutical Chemistry)

Supervised by

Prof. Dr. Samir M. El-Moghazy

Professor of Pharmaceutical Chemistry,

Faculty of Pharmacy,

Cairo University

Dr. Nagwa M. Abdelgawad

Associate Professor of Pharmaceutical

Chemistry, Faculty of Pharmacy,

Cairo University

Dr. Diaa A. Ibrahim

Researcher of Pharmaceutical Chemistry,

National Organization for Drug Control

& Research (NODCAR)

Dr. Nahla A. Hassan

Lecturer of Pharmaceutical

Chemistry, Faculty of Pharmacy,

Cairo University

Faculty of Pharmacy

Cairo University

2009

CP
CP

Approval Sheet

The thesis has been approved by the committee in charge on **14 / 09 / 2009**

1- prof. Dr. Raafat Milad Mohareb.

Professor of Organic Chemistry,

Faculty of Science,

Cairo University.

R. m. mohareb

2- prof. Dr. Safinaz El-Sayed Abas.

Professor of Pharmaceutical Chemistry,

Faculty of Pharmacy,

Cairo University.

Safinaz

3- Dr. Nagwa Mohamed Abdelgawad

Associate Professor of Pharmaceutical Chemistry,

Faculty of Pharmacy,

Cairo University.

Nagwa

Acknowledgement

*First and foremost to **God** for helping me finish this work.*

*I wish to express my thanks and sincere gratitude to **prof. Dr. Samir M. El-Moghazy**, prof. of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, for constructive supervision , helpful suggestions and continuous encouragement.*

*I am grateful to **Dr. Nagwa M. Abdelgawad**, Associate Professor of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, for her laborious efforts and continuous encouragement.*

*I am also greatly indebted to **Dr. Diaa A. Ibrahim**, Researcher of Pharmaceutical Chemistry, NODCAR., for suggesting the work and great effort he had done in accomplishing this work.*

*My deep appreciation to my colleagues in **NODCAR** for their support and encouragement.*

Dedication

- To My Father
- To My Mother & Sister
- To My Wife & My Son "Yousif"

Contents

Contents

Item	Page
Introduction	
A - Cancer	1
B - Causes of cancer	1
C - Treatment	3
Chemotherapy	4
1 Antimetabolites	5
1.1 DHFR Inhibitors (Antifolates).....	5
1.2 Purine antimetabolites.....	6
1.3 Pyrimidine antimetabolites.....	6
1.4 Thymidylate synthase inhibitors.....	7
1.5 Adenosine deaminase inhibitors.....	7
2 DNA-interactive compounds	8
2.1 Alkylating agents.....	8
2.1.1 Cross-linking agents.....	8
2.1.1.1 Nitrogen mustards.....	8
2.1.1.2 Oxazaphosphorines.....	9
2.1.1.3 Platinum complexes.....	9
2.1.1.4 Other alkylating agents.....	10

Item	Page
2.2 The DNA intercalating agents.....	11
2.2.1 Anthracyclines.....	12
2.2.2 Anthracentes.....	12
2.3 Topoisomerase inhibitors.....	12
2.3.1 Topoisomerase I inhibitors.....	13
2.3.2 Topoisomerase II inhibitors.....	13
2.4 DNA-cleaving agents.....	13
2.5 Antitubulin agents.....	14
2.5.1 Vinca alkaloids.....	15
2.5.2 The taxanes.....	15
3 Signal transduction inhibitors	15
3.1 Protein kinase inhibitors as anticancer agents.....	16
3.2 Classification of protein kinases.....	17
3.3 Functions of protein kinases.....	18
3.4 Mechanism of signal transfer	18
3.5 Regulation of kinases activity.....	19
3.6 Mechanisms of tyrosine kinases dysregulation in cancer.....	21
3.7 Tyrosine kinase inhibitors.....	24
3.7.1 BCR/ABL inhibitors: Imatinib (<i>Glivec</i>).....	24

Item	Page
3.7.2 EGFR inhibitors.....	25
3.8 Targeting Cyclin-Dependant Kinases (CDKs).....	26
3.9 CDK2 structure.....	28
3.10 The ATP binding site.....	30
3.10.1 Adenine region.....	31
3.10.2 Sugar pocket.....	31
3.10.3 Hydrophobic pocket (selectivity pocket).....	31
3.10.4 Hydrophobic channel.....	32
3.10.5 Phosphate binding region.....	32
Aim of the work	33
Literature review	
Synthesis of pyrimido[4,5-d]pyrimidine derivatives.....	38
Some common reactions of pyrimido[4,5-d]pyrimidine derivatives.....	60
Experimental	
Synthesized compounds.....	66
Scheme 1.....	70

Item	Page
Scheme 2.....	71
Experimental	72
 Discussion	
A- Molecular Modelling	
1- Structure preparation.....	92
2- Common features pharmacophore.....	93
3- Docking and binding energy calculations.....	101
B- Chemistry	104
C- Anti-tumor screening	113
 English summary	136
 References	142
 Arabic summary	

List of figures

Item	Page
Fig (1): Mechanism of protein kinase activation.....	20
Fig (2): Mechanisms of tyrosine kinases dysregulation in cancer	23
Fig (3): Cell cycle.....	27
Fig (4): Ribbon diagram of CDK2 apoenzyme refined to 1.8 Å resolutions (PDB access code: 1HCL).....	28
Fig (5): Sequence alignment of CDK1,2,5 and 9.....	29
Fig (6): ATP-binding site of protein kinases.....	30 , 34
Fig (7): Pharmacophore model (1).....	94
Fig (8): Pharmacophore model (2).....	97
Fig (9): Mapping of compound (7c) to pharmacophore (1)..	100
Fig (10): Mapping of compound (7c) to pharmacophore (2).	100
Fig (11): Hydrogen bond interactions of compound (7c) with the active site.....	103
Fig (12): Electrostatic potential interactions of compound (7c) with the active site.....	103
Fig (13): One Dose Mean Graph for compound (7c).....	132
Fig (14): Dose Response curves for 5 dose concentration of compound (7c).....	133
Fig (15): 5 Dose Mean Graph for compound (7c).....	134